key: cord-0254953-yyuz98qn
authors: Lengeler, C.; Burri, C.; Awor, P.; Athieno, P.; Kimera, J.; Tumukunde, G.; Angiro, I.; Tshefu, A.; Okitawutshu, J.; Kalenga, J.-C.; Omoluabi, E.; Akano, B.; Ayodeji, K. A.; Okon, C.; Yusuf, O.; Brunner, N. C.; Delvento, G.; Lee, T. T.; Lambiris, M.; Visser, T.; Napier, H. G.; Cohen, J. M.; Buj, V.; Signorell, A.; Hetzel, M. W.; Consortium, CARAMAL
title: Community access to rectal artesunate for malaria (CARAMAL): a large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda
date: 2021-12-11
journal: nan
DOI: 10.1101/2021.12.10.21266567
sha: d15b8d8df13ba658b429abdddeaac72c4e2ae94c
doc_id: 254953
cord_uid: yyuz98qn

The key to reducing malaria deaths in highly endemic areas is prompt access to quality case management. Given than many severe cases occur at peripheral level, rectal artesunate (RAS) in the form of suppositories was developed in the 1990s. RAS allows the rapid initiation of life-saving antimalarial treatment, before referral to a health facility with full case management capabilities. One randomized controlled trial published in 2009 showed a protective effect of RAS pre-referral treatment against overall mortality of 26%, but with significant differences according to study sites and length of referral. Two important issues remained unaddressed to-date: (1) whether the mortality impact of RAS observed under controlled trial conditions could be replicated under real-world circumstances; and (2) clear operational guidance for the wide-scale implementation of RAS, including essential health system determinants for optimal impact. From 2018 to 2020, the Community Access to Rectal Artesunate for Malaria (CARAMAL) project was conducted as a large-scale observational implementation study in Nigeria, Uganda and the Democratic Republic of the Congo (DRC). CARAMAL aimed to provide high-quality field evidence on the two issues above, in three remote settings with high malaria endemicity. In order to achieve this, a number of complementary study components were implemented. The core of the CARAMAL study was the Patient Surveillance System (PSS), which allowed to track cases of severe febrile illness from first contact at the periphery to a referral health facility, and then on to a Day 28 visit at the home of the patient. Community and provider cross-sectional surveys complemented the PSS. Here we describe in some detail RAS implementation, as well as the key CARAMAL study components and basic implementation experience. This manuscript provides an extensive reference document for the companion papers describing the impact, referral process, post-referral treatment and cost-effectiveness of the RAS intervention.

Mortality from malaria is due to uncomplicated disease from a Plasmodium infection left untreated 68 and progressing to severe disease and ultimately death [3, 4] . Mortality from untreated severe 69 malaria is very high, and varies according to epidemiological, biological and clinical severity factors 70 [5] [6] [7] . Our best estimate of case fatality ratios (CFR) for African children with confirmed severe 71 malaria disease and optimal treatment comes from the multi-centre AQUAMAT study [8] . Under 72 parenteral artesunate treatment, CFR among 230 patients was 8.5% at 28 days following 73 admission. On the other hand, CFR under routine treatment situations varies widely below or 74 above this value because of varying quality of care, more or less stringent severe malaria case 75 definitions, and lack of reliable cause-of-death estimates [6] . Effective clinical management of 76 severe malaria patients has a high potential for reducing case fatality from malaria, with an 77 estimated protective efficacy for routinely admitted children ranging from 76-87% [5] . In addition, 78 effective treatment can prevent sequelae including developmental impairment [9] , the 79 recrudescence of infections, and ultimately also the emergence and spread of resistant parasites 80 [10] . 81 82 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 7 study found increased mortality in older children and adults in Bangladesh, which was considered 167 to be a chance finding in a 2014 Cochrane review [23] . 168

In an accompanying commentary to [12] , von Seidlein [24] asked the question of whether these 170 results, obtained in the frame of a randomized clinical trial, were replicable in real-life settings. 171

Given the importance of reducing deaths from malaria in highly malaria-endemic areas, and given project tested the hypothesis that it is feasible to achieve reductions in severe malaria case fatality 187 ratios by delivering RAS through established routine health system platforms, without substantial 188 supportive interventions, and without unintended negative consequences. 189

Here we present a general description of the CARAMAL project, its research questions, detailed 191 methodology and overall operational results. The key findings and recommendations from the 192 scientific investigations of the CARAMAL project are presented elsewhere, with a focus on the 193 health impact of the large-scale roll-out of RAS [25] , referral processes and completion rates [26], 194 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 the quality of treatment at referral health facilities [Signorell et al. manuscript in preparation], . Given its size (over 14,000 episodes of severe fever 196 observed), its ability to follow these children for 28 days after enrolment into the study, and the 197 multiplicity of research tools, CARAMAL offered unique insight into the fate of children 198 experiencing severe febrile illnesses (including severe malaria) in remote locations in Africa. The 199 study also illuminated the many health system characteristics that led either to successful or to 200 scientific support on specific aspects of the project, and was responsible for turning the generated 220 evidence into policy and implementation guidelines. 221 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Country and site selection The study sites in the three countries were selected based on the evaluation by UNICEF -and 241 vetted by national authorities -of ongoing iCCM operations, case numbers, and security 242 considerations. All implementation sites were considered remote based on distance to tertiary 243 health facilities, to reflect settings in which RAS could have the greatest potential based on 244 previous findings [12] . To provide some degree of geographical, cultural, linguistic and health 245 system diversity, one country was selected from West, Central and East Africa, respectively. Fig 1  246 also shows key climatic data, as well as malaria infection rates in children under five years of age, 247 as measured in the frame of the CARAMAL study. The three sites were shown to have a high level 248 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 of endemicity: the community parasite rates in children under 5 years were 40-57% in DRC, 38-249 61% in Nigeria and 53-78% in Uganda (Fig 1) . 250

Health system environment 252 Health services in the study sites consisted of a network of formal health facilities, including 253 primary health centres (PHC) that offered mainly preventive and curative outpatient services, and 254 referral health facilities with higher-level medical capabilities and usually inpatient wards (Table 1) . 255

In all three countries, and following national guidelines, comprehensive treatment for severe 256 malaria patients was only meant to be provided in referral health facilities. Private for-profit clinics 257 and pharmacies were present in each site in varying numbers. Unfortunately, we could not cover 258 these fully in the frame of the CARAMAL work because this would have exceeded the available 259 resources. But patient visits to these facilities were elicited in the various data collection 260 instruments. 261 262 RAS was implemented in all Primary Health Care (PHC) facilities. RAS was also implemented in 263 each study site through Community Health Worker (CHW) programmes offering basic preventative 264 and curative services, in line with global and national iCCM guidance. The CHWs implemented 265 iCCM algorithms, which could be leveraged in the frame of the CARAMAL project to implement 266 RAS [27] . In this manuscript, community-based providers in all three countries are called "CHW", 267 even though there was a different terminology in each country. Their numbers also differed 268 significantly by country (Table 1) where other formal public health providers are far away (i.e. considered hard-to-reach). In Uganda, 275 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint the national policy is that two CHWs are located in every village, explaining their high coverage. 276 Table 1 illustrates the significant differences in the health care structure between the three sites. 277 278 purchased and shipped to the project countries by UNICEF. The manufacturer's dosage 287 recommendations were one suppository of 100 mg for children between 6 months and 3 years, 288 and two suppositories for children from 3 to 6 years of age. In the three countries, RAS pre-referral 289 treatment is part of the countries' current national malaria treatment policy, though not yet 290 implemented at scale. In the study areas, RAS was rolled out at community level in early 2019 291 through the two channels list above. 292 293 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10. 1101 /2021 In preparation for the roll-out of RAS, MMV developed job aids and training materials for the 294 appropriate management of children experiencing symptoms of severe febrile illness/suspected 295 severe malaria (Fig 2) . According to WHO/UNICEF iCCM guidelines [27] , patients eligible for pre-296 referral RAS are defined as follows: age below 5 years, fever or a history of recent fever, plus one 297 of the following general danger signs : lethargy/unconsciousness, not able to feed or drink, 298 convulsions, repeated vomiting. While local iCCM guidelines (e.g. in Nigeria) included a few 299 additional danger signs, it was this broad clinical picture of severe febrile illness -especially the 300 inability to tolerate oral medications, that prompted the administration of RAS and the issuing of a 301 referral notice to a higher level health facility. Of note is that (1) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint 13 Supportive health system interventions 322 A limited number of essential supportive interventions were implemented in addition to introducing 323 RAS, to facilitate rollout and foster appropriate higher-level care in the study sites. In DRC, 324 additional injectable artesunate had to be distributed to referral facilities (27,000 vials in 2019) even 325 though this was meant to have already been included in ongoing malaria control programmes. In 326 Nigeria, a color-coded, two-way referral form was printed to improve communication between 327

CHWs and referral health facility staff; and an existing emergency transport system for emergency 328 obstetric care was extended to allow the transport of severely ill children. In Uganda, district-level 329 (parish) coordinators were engaged to support data collection from CHWs and support 330 replenishment of their RAS stock. These additional health system strengthening activities were 331 limited to a few essential supplies and processes by design due to scalability considerations, and 332 purposely did neither include large-scale supply chain management support nor fundamental 333 improvement of referral services given the aim of evaluating the effect of introducing RAS under 334 real-world circumstances. The issue of transport subsidies to facilitate referral completion was 335 discussed within the team, with relevant national authorities and the donor. For the same 336 considerations as above it was deemed that additional health systems interventions such as 337 transport subsidies or purchase of additional transport modalities (e.g. motorcycles), while 338 potentially life-saving, would be unsustainable in the long-run and thus outside the aim of 339 generalizability of the CARAMAL project. The overall conceptual framework for evidence generation was the continuum of care for severe 365 febrile illness: starting with the recognition of a child's illness at home, then care-seeking and case 366 management outside the home, and ending 28 days later with the determination of the health 367 status of the child (Fig 3) . This continuum was broken down into discrete 'steps' that could be 368 measured as part of a real-world effectiveness study. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint In addition, children <5 years directly seeking care at a referral facility and admitted with a 387 diagnosis of "severe malaria" were also enrolled. Even though these children were not eligible for 388 RAS pre-referral treatment, and thus not part of the primary analysis, they were included in the 389 CARAMAL study to understand their comparative treatment seeking behaviour, diagnosis, and 390 case management at the referral facility. Including these patients also allowed for a comparison 391 between case numbers and CFR at community-based providers versus referral facilities, and a 392 more comprehensive calculation of severe febrile illness / severe malaria rates. 393 394 Data collection methods 395 Data were collected through a set of complementary activities aligned with the roll-out of RAS in 396 the study areas (Fig 4) . The core of the CARAMAL evidence generation was the PSS, described in detail below. Patients 402 were enrolled in the PSS over the entire study period, both before and after the roll-out of RAS. 403

Data on molecular markers of artemisinin drug resistance were collected in the frame of the PSS 404 (see below). In addition, one health care provider survey (HCPS) and one household survey (HHS) 405 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint took place during the pre-RAS period, and two each in the post-RAS implementation period. In 406 DRC, the last HCPS and HHS were only conducted in 2 out of the 3 sites. Data for the costing 407 study were collected in 2020. Data collection activities are described in detail below; a 408 comprehensive list of indicators related to each activity is provided in Supporting information S2 409 Table. The day 28 visit and the monitoring of patients during their admission at referral facilities were the 458 primary data sources for the monitoring and evaluation of patients. In addition, selected data points 459 were collected directly from the enrolling community-based providers, based on their routine 460 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 records. This included crucially information on RAS administration. Data was collected in ODK 461 Collect (https://opendatakit.org/) on tablet computers. months was based on the detection of a 30% decrease in case fatality across the three project 473 countries following the roll-out of RAS, with 80% power and α = 0.05. Rounded up, this translated 474 into 1,600 cases in the pre-RAS at baseline phase and 4,600 post-RAS roll-out, across the three 475 countries (total 6,200). We also assumed that only 40% of all severe malaria cases would be 476 enrolled into the PSS at CHW/primary health facility level and followed up on day 28. For 477 measuring changes in CFR, a pooled analysis with data from the three countries was planned, 478 while other less sample-size demanding indicators were calculated per country. In order to obtain 479 this number of severe malaria cases, a total population of 2.2 million individuals including at least 480 400,000 children under 5 years needed to be considered. This target was exceeded (see Fig 1) . 481

Further calculations per country confirmed that this sample size was large enough that other 482 conditions such as severe febrile illness, and improvements in referrals, could be detected with at 483 least the same probability (calculations not shown). 484 485 Activity 2: Health Care Provider Surveys (HCPS) 486 HCPS were conducted annually to assess the severe malaria case management capacity of the 487 local health system. Two survey instruments were completed by each provider: (1) a structured 488 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint checklist assessing the availability of essential medical supplies and equipment, human resources, 489 infrastructure and documentation in their health facility, and (2) a questionnaire aimed at the 490 providers themselves, and containing questions on demographics, education and training, work 491 experience, supervision, training received, knowledge, attitudes and practices relevant to febrile 492 case management (incl. diagnostic algorithm and RAS treatment guidelines), and implementation 493 experience with these treatment guidelines. Both forms were designed for electronic data entry 494 using ODK. All included health care providers signed an informed consent form before the 495 interview. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Activity 3: Household surveys (HHS) 517 HHS were carried out annually to assess malaria control intervention coverage, caretaker 518 treatment seeking behaviour, caretakers' knowledge of and attitudes towards RAS, and to 519 measure prevalence of malaria and anaemia in the population < 5 years of age (using the same 520 procedure as during the Day 28 visit). In each household, the household head and 521 parents/caregivers of children < 5 years of age were eligible to participate in face-to-face structured 522 interviews, after informed consent. All forms were designed for electronic data entry using ODK. 523

Sampling and sample size calculation for household surveys: Households were selected using a 524 two-stage random sampling approach (village-household), whereas the sampling frames consisted 525 of all villages in the study area and all households in the village with at least one child < 5 years. 526

Treatment seeking from formal health facilities in case of fever in children <5 years was assumed 527

to be between 15% [32] to over 75% [33] . For the calculation of the sample size an increase in 528 treatment-seeking from 15% (minimum scenario pre-implementation) to 20% post-implementation 529 of RAS, with 80% power and α = 0.05 was aimed for. A minimum of 906 household survey 530 responses per country and survey round was required. for the routine monitoring of process indicators. These included procurement records, supervision 543 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 reports, routine reports and provider geo-locations, which were on occasion incomplete for a 544 documented in the study settings in 2017, this prospect was of great concern to WHO and public 558 health practitioners. Of special concern in the frame of the CARAMAL project was the fact that 559 RAS is a monotherapy, and that the widespread use of artemisinin monotherapies could increase 560 drug pressure. The same problem is obviously also arising from parenteral use of artesunate, the 561 currently recommended drug of choice for severe malaria, if not followed by an oral ACT as per 562 WHO recommendations [10] . According to market data provided by MMV 563 (www.severemalaria.org/severe-malaria-market-situation), the expected annual market for RAS is 564 one million units per year, against 25 million doses of injectable artesunate. Hence the issue of 565 monotherapy is potentially more related to the uncontrolled use of injectables rather than RAS. 566 567 To monitor prospectively the frequency of resistance markers in the three study settings, a 568

complementary study was implemented in collaboration with the WHO Global Malaria Programme 569 (GMP). The project sampled children of different groups with malaria in the frame of the PSS at 570 two time points (see Fig 4 above) to measure the prevalence of molecular markers of artemisinin 571 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint 23 600 Informed consent from the participant's parent or guardian was obtained prior to the inclusion into 601 the PSS. Preliminary oral consent was asked at the primary care level because of the urgency of 602 the child's clinical condition. This oral consent was followed by a written consent either at the 603 referral health facility, or during the day 28 follow-up at home, whatever came first. 604 605 Written consent was obtained separately from health workers prior to participating in the HCPS 606 (Activity 2), and from household heads and parents/guardians of children < 5 years prior to 607 participating in the HHS (Activity 3). 608 609 610 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Results and discussion Almost half of the children were enrolled directly at a referral health facility (6,131, 45%) ( 619 Table 2 ), while CHWs enrolled 4,415 (55%) and PHCs contributed 3,212 (23%) enrolments. In 620 Nigeria, most enrolments came from RHFs. In DRC, a minority of enrolments came from CHWs (a 621 reflection of the small number of these providers), while in Uganda, more enrolments came from 622

CHWs than from PHCs, probably as a result of their large number (see also Table 1 ). Particularly 623 in Nigeria, the proportion of PHC enrolments increased from pre-RAS (11%) to the post-RAS 624 period (26%), but overall more children were recruited directly at the RHF level. 625 626 630 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 10.

WHO. WHO Guidelines for malaria. Geneva: World Health Organization, 2021. 914 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

2020: 20 years of global progress and challenges. Geneva: 882 World Health Organization, 2020. 883 2. WHO. Global technical strategy for malaria

Why do some African children develop severe malaria? 886

Malaria infection 889 and severe disease risks in Africa

Protective efficacy of malaria case management and 892 intermittent preventive treatment for preventing malaria mortality in children: a systematic review 893 for the Lives Saved Tool

Incidence and admission 897 rates for severe malaria and their impact on mortality in Africa

Clinical and 901 laboratory predictors of death in African children with features of severe malaria: a systematic 902 review and meta-analysis

Artesunate versus quinine in the treatment of severe falciparum malaria in African children 906 (AQUAMAT): an open-label, randomised trial

Developmental impairments following severe falciparum malaria in children

Care-915 seeking patterns for fatal malaria in Tanzania

referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled 919

Effective coverage and 922 systems effectiveness for malaria case management in sub-Saharan African countries

Artesunate versus quinine for 926 treatment of severe falciparum malaria: a randomised trial

Artesunate versus quinine for treating severe 929 malaria

Access to health 932 care in contexts of livelihood insecurity: a framework for analysis and action

Efficacy and 936 tolerability of a sequential, artesunate suppository plus mefloquine, treatment of severe falciparum 937 malaria

rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria 941 in African children and adults: a randomised study

Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with 945 moderate malaria

An operational 983 comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and 984 health centres in the Democratic Republic of Congo: the MATIAS study

Epub 2015/05/31

Statistical Methods for Rates and Proportions

Routine data for disease surveillance in the 990 undeveloped region of the OR Tambo district of the Eastern Cape Province

Obstacles to prompt 993 and effective malaria treatment lead to low community-coverage in two rural districts of Tanzania

The impact of 997 delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A 998 systematic review and a pooled multicentre individual-patient meta-analysis

Malaria Diagnosis and Management in Burkina Faso

Observational Study

Management Matters: A Leverage Point for Health 1006

Systems Strengthening in Global Health

High-quality 1010 health systems in the Sustainable Development Goals era: time for a revolution

Epub 2018/09/10

Raising a mirror to quality of care in Tanzania: the five-star 1014 assessment

Details on place of recruitment, age and sex-distribution of the enrolled children are given in the 631Supporting information S3 Table. Enrolments Some key results are reported below. In DRC, the 100 mg RAS products from Cipla TM and Strides 641Pharma Science TM received marketing authorization in June 2017 and September 2017, 642 respectively. RAS coverage increased rapidly and remained high after its initial introduction in March 643 2019 (Fig 6a) . In Nigeria, the 100 mg RAS product from Strides Pharma Science TM received 644 marketing authorization in January 2019, and the product from Cipla TM in October 2019. Two 645 procurements were initially anticipated to cover the needs of the study areas through the end of 646 implementation in October 2020. However, civil protest and riots in July-August 2020 resulted in the 647 looting of RAS storage facilities in Adamawa. A total of 7,577 RAS units were lost in the attack. RAS 648 coverage increased inconsistently after introduction in April 2019 (Fig 6b) . In Uganda, both 100 mg 649 RAS products from Cipla TM and Strides Pharma Science TM received marketing authorization in 650November 2018. RAS coverage increased steadily after its introduction in April 2019, and a high 651 RAS coverage was reached after 3-4 months (Fig 6c) . Neither the timing of RAS distribution and 652 trainings, nor other individual factors and contextual circumstances explained the observed patterns 653 of RAS administration (data not shown). 654 655 RAS was distributed to health workers at the community level immediately following their initial 656 trainings. A total of 126,904 RAS units were procured for the three countries, and 91,189 units 657 were distributed to over 8,000 trained CHWs and primary healthcare workers. The remaining RAS 658 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 27 reduced the shelf-life of RAS. Ongoing stability tests are being conducted and will be reported 688 elsewhere (MMV manuscript in preparation). 689 690 A lockdown due to the COVID-19 pandemic was issued in Nigeria on the 30 th of March 2020 691 restricting the movement of people and supplies. This has undoubtedly contributed to the drop in 692 RAS administration and PSS enrolments during spring 2020 (Fig 6b) . 693 694 Uganda: Quarterly review meetings at PHC facility level were set up to track commodities for 695reporting to the national level. Since this system was not responding fast enough, a monthly district-696 level (parish) coordinator meeting was set up by CHAI and implemented to support overcoming 697 logistics challenges. Supervision of CHWs was conducted in parallel with monthly parish coordinator 698 meetings. Initially, CHWs were provided with one pack of RAS per quarter, based on predicted 699 numbers of severe cases. This quantity was quickly shown to be insufficient, and subsequently 700CHWs were given at least two packs per quarter. According to the HCPS midline and endline 701 surveys, over 85% of CHWs and 96% PHC facilities reported receiving at least one supervisory visit 702 during the last 6 months. COVID-19 had also an impact on the movement of persons and on the 703 supply chain from April to June 2020. In Fig 6c, Evidence on dosing with RAS of study children was collected from slightly over 1000 study children 713 (Fig 7) . According to the manufacturer's recommendations, children between 6 months and 3 years 714 should receive one 100 mg suppository, while children from 3 to 6 years of age should receive two 715 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint 28 suppositories. This recommendations could be leading to variable dosing because of low-weight-for-716 age children. In the CARAMAL study, the recommended dosing was not universally adhered to, and 717 many children were under-dosed. In DRC, 83% of children over 3 years that were administered RAS 718 received one suppository instead of two. In Nigeria the situation was best with only 32% of children 719 over 3 years receiving one suppository, while in Uganda this percentage was 55%. and were critical to a functioning RAS supply line. However, carrying out regular supervision visits 735 was challenging from an operational, logistical and financial perspective -despite the fact that in 736 all three settings this was a routine task expected to be performed by the health system. 737 3. Need for regular restocking of RAS at the CHW level and mechanisms for internal redistribution, 738given the high variability in RAS needs: some CHW regularly used RAS, while others did not use a 739 single dose during the study period. (Table 2) , and given the estimated number of children of that age 757 group in the three settings (Table 1) . DRC = 5,540 cases /145,107 children U5 = 0.038 or 38 per 758 1,000 for the 27 months of the study period; or 16.9 per 1,000 and per year. Nigeria: 759 1,505/130,430 = 0.012 or 12 per 1,000 for the study period; or 5.3 per 1,000 and per year. 760 Uganda: 6,713/200,518 = 0.033 or 33.5 per 1,000 for the study period; or 14.9 per 1,000 per year. 761These estimates are only approximations with substantial margins of error for at least four reasons. 762Firstly, the actual number of cases of febrile illness seen through the PSS is certainly below the 763 real number occurring in the community, since not all children were brought to public providers for 764 treatment. Unfortunately, we had no way to estimate this independently in this large population. 765Secondly, varying case definitions among the three sites undermined the representativeness of the 766 number of reported cases of "severe febrile illness" (see also . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint 30 access to prompt and effective antimalarial treatment at primary level is likely to influence the rate 770 of progression from mild to severe disease [6, 13, 34] . Fourthly, up-to-date and accurate census 771 figures were not available for the study areas, and hence the denominators were only an 772 estimation based on best available data from public sources. 773 774 All other parameters being equal, truly severe febrile episode case numbers were likely to be 775 underestimated in Nigeria (low numbers of enrolled children with probably higher average severity 776 in patients leading to high CFR (Fig 8) and overestimated in Uganda (low CFR indicative of low 777 average severity in patients), while the DRC estimates were in-between. Nevertheless, these 778 community severe febrile illness rates are probably among the best produced for any African 779 setting to-date, and should have some utility. 780

Overall Case Fatality Rates (CFR)

The CFR differed significantly between the three countries, and in DRC also between both 783 enrolment groups (Fig 8) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 . A small but potentially significant difference 800 between the two guidelines is that the target age group is different: below 5 years for iCCM, below 801 6 years in the WHO RAS guidelines. We did not assess the effect of this difference in the 802 CARAMAL study. 803 804 This lack of overlap between the two case definitions has at least two implications for practice. 810Firstly, the inability to estimate correctly the true rates of severe malaria in the community has 811 already been noted above, and represents an important limitation for tracking progress in malaria 812 disease control. Possibly, recommending systematically an mRDT to febrile children with 813 signs/symptoms of disease severity, could prevent unnecessary RAS pre-referral treatment. This 814 approach has been shown to be feasible and safe [35] . This was also the case in the CARAMAL 815 study. 816 817 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 32 Secondly, there seem to be a case for exploring in more detail the significance of some of the 818 iCCM severity signs in children for their prognostic value, in a way similar to what was done for 819 clinical and laboratory parameters of severe malaria [7]. This could for example be assessed for 820 "Refusal to feed/breastfeed" or "Repeated vomiting", which are not strictly indicators of severe 821 disease. This could lead to re-assessing their value for initiating systematically a referral, with all its 822 difficulties and uncertainties, and possibly recommend a wait-and-see strategy instead, with or 823 without RAS administration. 824 825 826

With over 9,000 episodes of severe febrile illness enrolled at the primary care level, the CARAMAL 828 project aimed to document comprehensively key determinants of RAS effectiveness. The present 829 project overview presented the project scope, objectives, methodological approaches, RAS 830 implementation, and gave some key operational results. Using a comprehensive treatment seeking 831 framework for severe febrile illness/severe malaria, the CARAMAL project documented 832 systematically patients, communities and health systems in three remote, highly malaria-endemic 833 setting (in DRC, Nigeria and Uganda). We also documented the RAS under-dosing problem, as 834 well as the difficulties of getting enough RAS doses to all relevant health care workers in time. 835Finally, the comprehensive Patient Surveillance System was used to calculate empirical rates of 836 severe febrile illness, as well as compute fatality rates of these patients, which were in excess of 837 published values for hospitalized patients in two of the three countries (DRC and Nigeria). 838 839 Effective case management for severe malaria episodes requires a large number of actions to be 840 completed in succession, including the availability of at least five commodities: an mRDT and RAS 841 at primary level, a confirmatory test for malaria at the RHF, injectable artesunate (or any other 842 approved parenteral drug) plus the required supportive treatments, and finally a full course of an 843ACT. This continuum of care was comprehensively documented by the CARAMAL project. As 844 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint 33 noted repeatedly elsewhere, improving the functioning of health facilities at all levels, as well as 845 strengthening other sources of care (for example in the private sector), is key to lasting 846 improvements of health in Africa, including for malaria [36] [37] [38] . A specific issue raised in the 847 CARAMAL study was the non-overlapping case definitions between severe febrile illness and 848 severe malaria, and we highlighted two practical issues arising from this. The CARAMAL consortium's experiences in rolling out RAS in the project countries generated a 857 comprehensive understanding of specific operational challenges that other countries will confront, 858 as well as potential solutions for overcoming them. Hence, it is hoped that CARAMAL will make a 859 lasting contribution to improving malaria disease and mortality in the most highly malaria-endemic 860 countries in the world. 861 862 863 864 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 34 Acknowledgements 865We thank all the children and their caregivers who agreed to participate in this study; the health 866 workers and local and national health authorities who provided their support. Individuals who 867 contributed to this work are listed under Supporting information S1 

The CARAMAL Project was funded by Unitaid (grant reference XM-DAC-30010-CHAIRAS). The 874 funder had no role in study design, data collection and analysis, decision to publish, or preparation 875 of the manuscript. 876All authors declared not having any financial relationships with any organizations that might have 877 an interest in the submitted work in the previous three years, nor any ther relationships or activities 878 that could appear to have influenced the submitted work. 879 880 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021.. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint 39 Supporting information captions 1018 1019 S1 Table: Authors included under the group name "CARAMAL consortium". 1020 1021 S1 Fig: Detailed . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.10.21266567 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display th (which was not certified by peer review) preprint